Curated News
By: NewsRamp Editorial Staff
November 16, 2026

Rodeo Nurse Practitioner Champions COPD Awareness with Dupixent

TLDR

  • Sanofi and Regeneron's Dupixent offers a competitive edge for COPD patients with high eosinophils by reducing flare-ups and improving breathing in as little as two weeks.
  • Dupixent (dupilumab) is added to standard COPD inhalers and works by targeting eosinophilic inflammation, requiring healthcare provider guidance for proper use.
  • Sanofi and Regeneron's Dupixent helps COPD patients regain daily activities and quality of life, offering hope for better breathing and fewer flare-ups.
  • Nurse practitioner and rodeo competitor Corinne Young draws parallels between COPD and rodeo, highlighting unpredictability and the value of added treatment like Dupixent.

Impact - Why it Matters

COPD affects millions worldwide, and many patients continue to experience flare-ups despite standard inhaler therapy, leading to reduced quality of life and uncertainty. This news matters because it underscores the importance of recognizing inadequately controlled COPD and having open conversations with healthcare providers about emerging treatment options like biologics. For patients, it offers hope that add-on therapies such as Dupixent may help reduce flare-ups and improve daily functioning, allowing them to engage more fully in life’s activities. It also highlights the need for personalized care and shared decision-making in chronic disease management.

Summary

In a new awareness campaign, Sanofi and Regeneron are drawing on the experiences of a nurse practitioner and a patient to highlight the challenges of inadequately controlled chronic obstructive pulmonary disease (COPD). Corinne Young, a pulmonology specialist who also competes in team roping, compares the unpredictability of COPD flare-ups to the rodeo, noting that patients often don’t know when breathing difficulties will disrupt their daily activities. Mark H., 60, who has lived with COPD since 2010, shares how the condition forced him to step back from hobbies and retire early, saying he felt like “this is my life now.” The core message is that ongoing flare-ups despite treatment may signal inadequately controlled COPD and should prompt a conversation with a healthcare provider about additional options.

Young encourages patients to discuss all symptoms and how often COPD impacts their daily life so that healthcare providers can assess the full picture and determine whether an add-on treatment may be appropriate. The release notes that treatment options have expanded, and some patients may be candidates for a biologic such as Dupixent® (dupilumab), which is approved for adults with inadequately controlled COPD and a high number of blood eosinophils. Dupixent is not used to relieve sudden breathing problems and does not replace an inhaled rescue medicine. Young says some patients who added Dupixent to their COPD inhalers experienced reduced flare-ups, better breathing in as little as two weeks, and improved quality of life. Mark adds that after adding Dupixent, his breathing feels deeper and he is doing more of the things he loves.

The release includes important safety information, warning that Dupixent should not be used by anyone allergic to dupilumab or its ingredients, and it lists potential side effects such as allergic reactions, eye problems, and joint aches and pain. Patients are advised to tell their healthcare provider about all medical conditions and medications before starting treatment. For more information, visit Dupixent.com/COPD, and to report negative side effects, visit www.fda.gov/medwatch. Full Prescribing Information and Patient Information are available. The campaign is sponsored by Sanofi and Regeneron.

Source Statement

This curated news summary relied on content distributed by NewsUSA. Read the original source here, Rodeo Nurse Practitioner Champions COPD Awareness with Dupixent

Blockchain registration record for this content